Artios is a leading DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. The Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery, including the discovery and early development of the PARP inhibitor Olaparib. It has a unique partnership with Cancer Research UK (CRUK), and collaborations with leading DNA repair researchers worldwide, such as The Institute of Cancer Research (ICR), London, the Netherlands Cancer Institute (NKI) and the Crick Institute, London. Artios is building a pipeline of next-generation DDR programs to target hard to treat cancers, including its ATR inhibitor ART0380 in treating DDR defective tumors, which is in a Phase 1 clinical study, and the potential first-in-class Polθ inhibitor ART4215 for monotherapy and combination treatments.

Artios Pharma

Artios Pharma